FDA Approves Daraxonrasib, First Targeted Therapy for Metastatic Pancreatic Cancer
Revolution Medicines' daily pill blocks RAS G12 mutations driving most tumors, nearly doubling median survival to 13.2 months versus chemotherapy's 6.6.
- RASolute 302 trial tested daraxonrasib against chemotherapy in previously treated metastatic pancreatic cancer.
- FDA granted Breakthrough Therapy, Orphan Drug, and National Priority Voucher status to speed review.
- Nearly 90% of pancreatic tumors carry RAS mutations, the protein this drug blocks.
Why it matters: The company declared commercial launch readiness before approval, proof the outcome was decided in advance.